HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Scott N Gettinger Selected Research

brigatinib

9/2022Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
12/2021Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
11/2020Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
1/2020Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
11/2018Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
10/2018Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
8/2017Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
12/2016Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Scott N Gettinger Research Topics

Disease

35Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2024 - 01/2010
32Neoplasms (Cancer)
04/2024 - 01/2008
10Lung Neoplasms (Lung Cancer)
11/2023 - 07/2013
7Brain Neoplasms (Brain Tumor)
12/2021 - 01/2016
6Disease Progression
09/2021 - 01/2017
6Neoplasm Metastasis (Metastasis)
01/2020 - 10/2013
5Melanoma (Melanoma, Malignant)
01/2020 - 06/2012
3Adenocarcinoma of Lung
01/2021 - 09/2013
3Pneumonia (Pneumonitis)
01/2020 - 07/2016
2Renal Cell Carcinoma (Grawitz Tumor)
01/2020 - 10/2019
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2019 - 04/2013
2Colitis
01/2017 - 07/2016
2Fatigue
07/2016 - 06/2015
2Colorectal Neoplasms (Colorectal Cancer)
11/2015 - 06/2012
2Body Weight (Weight, Body)
10/2015 - 06/2012
1Diarrhea
12/2020
1Exanthema (Rash)
12/2020
1Central Nervous System Diseases (CNS Diseases)
01/2020
1Smoldering Multiple Myeloma
01/2020
1Pericarditis
01/2019
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2019
1Cardiotoxicity
01/2019
1Pityriasis Rubra Pilaris
08/2018
1Exfoliative Dermatitis (Erythroderma)
08/2018
1Inflammation (Inflammations)
01/2018
1Adrenal Insufficiency (Adrenal Gland Hypofunction)
01/2017
1Hypertension (High Blood Pressure)
12/2016
1Acute Kidney Injury (Acute Renal Failure)
07/2016
1Hyperkalemia
07/2016
1Sarcoidosis (Schaumann Disease)
05/2016
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
11/2015
1Pericardial Effusion
06/2015
1Leukopenia
06/2015
1Hypoxia (Hypoxemia)
06/2015
1Dyspnea (Shortness of Breath)
06/2015
1Neutropenia
06/2015
1Sarcoma (Soft Tissue Sarcoma)
09/2013
1Prostatic Neoplasms (Prostate Cancer)
06/2012
1Carcinogenesis
06/2010
1Thyroid Neoplasms (Thyroid Cancer)
06/2010

Drug/Important Bio-Agent (IBA)

9NivolumabIBA
11/2023 - 06/2015
8brigatinibIBA
09/2022 - 12/2016
7Immune Checkpoint InhibitorsIBA
04/2024 - 02/2015
7CrizotinibIBA
12/2021 - 12/2016
6Anaplastic Lymphoma KinaseIBA
11/2020 - 09/2013
5IpilimumabIBA
11/2023 - 05/2016
5atezolizumabIBA
01/2020 - 11/2014
5B7-H1 AntigenIBA
01/2020 - 01/2014
4PlatinumIBA
09/2021 - 04/2010
4Tyrosine Kinase InhibitorsIBA
01/2021 - 01/2016
4pembrolizumabIBA
01/2020 - 07/2016
4ErbB Receptors (EGF Receptor)IBA
01/2019 - 09/2013
3Biomarkers (Surrogate Marker)IBA
01/2021 - 10/2016
3LigandsIBA
01/2019 - 06/2012
2Adrenal Cortex Hormones (Corticosteroids)IBA
01/2020 - 07/2016
2Circulating Tumor DNAIBA
01/2018 - 07/2012
2Lipase (Acid Lipase)FDA Link
01/2017 - 12/2016
2Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2016 - 11/2012
2Sorafenib (BAY 43-9006)FDA Link
10/2016 - 06/2010
2Bevacizumab (Avastin)FDA Link
11/2015 - 11/2012
2Cisplatin (Platino)FDA LinkGeneric
11/2015 - 04/2010
2Docetaxel (Taxotere)FDA Link
10/2015 - 04/2010
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2021
1veliparibIBA
01/2021
1osimertinibIBA
01/2021
1Cetuximab (Erbitux)FDA Link
12/2020
1AfatinibIBA
12/2020
1bempegaldesleukinIBA
01/2020
1Interleukin-2 (IL2)IBA
01/2020
1Monoclonal AntibodiesIBA
10/2019
1AcitretinFDA Link
08/2018
1MK 2206IBA
10/2016
1AZD 6244IBA
10/2016
1Transaminases (Aminotransferases)IBA
07/2016
1Pemetrexed (MTA)FDA Link
11/2015
1regorafenibIBA
11/2015
1Phosphotransferases (Kinase)IBA
11/2015
1Immunoglobulins (Immunoglobulin)IBA
06/2015
1Albumin-Bound PaclitaxelFDA Link
06/2015
1Dihydrotachysterol (AT 10)IBA
06/2015
1Sirolimus (Rapamycin)FDA Link
06/2015
1TOR Serine-Threonine KinasesIBA
06/2015
1Programmed Cell Death 1 ReceptorIBA
02/2015
1Messenger RNA (mRNA)IBA
01/2014
1AntibodiesIBA
01/2014
1AntigensIBA
07/2013
1Viral AntigensIBA
07/2013
1DNA (Deoxyribonucleic Acid)IBA
07/2012
1Sunitinib (Sutent)FDA Link
06/2010
1Proteins (Proteins, Gene)FDA Link
06/2010

Therapy/Procedure

20Therapeutics
04/2024 - 01/2010
14Immunotherapy
04/2024 - 07/2013
7Drug Therapy (Chemotherapy)
09/2021 - 01/2008
6Radiotherapy
01/2020 - 01/2008
2Chemoradiotherapy
01/2021 - 01/2020
1Cell- and Tissue-Based Therapy (Cell Therapy)
04/2024
1Precision Medicine
01/2020
1Cryotherapy (Therapy, Cold)
12/2018
1Immunomodulation
10/2017
1Castration
06/2012